Repligen Co. (NASDAQ:RGEN) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 98.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 206 shares of the biotechnology company's stock after selling 13,770 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Repligen were worth $30,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Ballentine Partners LLC grew its holdings in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after buying an additional 81 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after buying an additional 100 shares in the last quarter. Utah Retirement Systems grew its holdings in shares of Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 100 shares in the last quarter. Finally, Peapack Gladstone Financial Corp grew its holdings in shares of Repligen by 5.2% during the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after buying an additional 103 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Trading Down 1.9%

RGEN traded down $2.30 during trading on Friday, hitting $118.15. 615,767 shares of the company's stock were exchanged, compared to its average volume of 740,875. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The stock has a 50 day moving average price of $130.28 and a 200 day moving average price of $144.49. The firm has a market cap of $6.64 billion, a P/E ratio of -231.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. As a group, analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on RGEN shares. Wall Street Zen upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Royal Bank of Canada lowered their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Evercore ISI started coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price for the company. Canaccord Genuity Group lowered their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Finally, TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.